Novolog (Pharm UP 1966) Ltd. (IL:NVLG)
TASE:NVLG
Want to see IL:NVLG full AI Analyst Report?
NVLG Stock Chart & Stats
126.20
>-0.01(-0.31%)
At close: 4:00 PM EST
126.20
>-0.01(-0.31%)
Day’s Range― - ―
52-Week Range79.10 - 154.63
Previous CloseN/A
Volume351.22K
Average Volume (3M)641.09K
Market Cap
₪408.70M
Enterprise Value421.70M
Total Cash (Recent Filing)₪163.20M
Total Debt (Recent Filing)₪176.20M
Price to Earnings (P/E)115.3
Beta0.67
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.05%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding510,874,760
10 Day Avg. Volume285,794
30 Day Avg. Volume641,093
Financial Highlights & Ratios
PEG Ratio-1.74
Price to Book (P/B)1.80
Price to Sales (P/S)0.36
P/FCF Ratio-18.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageDebt-to-equity near 0.5 indicates conservative financial structure, giving the company flexibility to fund operations, service obligations and invest without heavy refinancing risk. Over 2-6 months this reduces insolvency risk and supports strategic moves or sustained dividends.
Strong TTM Cash FlowA large recent rebound in operating and free cash flow provides tangible liquidity to support capex, dividends and deleveraging. Persistent cash conversion relative to net income enhances funding optionality and resilience against short-term revenue softness if maintained.
Positive Operating ProfitabilitySustained positive EBIT/EBITDA margins show the core business still generates operating profit despite revenue pressure. Modest margin improvement in the TTM suggests management can extract efficiencies and that the business retains structural profitability potential over the medium term.
Bears Say
Revenue ContractionOngoing top-line decline erodes scale and reduces operating leverage, making fixed costs harder to cover and compressing long-term earnings potential. Unless revenue trends stabilize or reverse, sustained shrinkage will constrain reinvestment, margin recovery and growth initiatives.
Sharply Compressed ReturnsA collapse in ROE shows capital is generating far less profit than historically, signaling impaired efficiency or structural margin decline. Lower returns limit the firm's ability to justify reinvestment, maintain dividend levels sustainably, and attract capital for growth over the medium term.
Volatile Cash GenerationHigh volatility in operating and free cash flow undermines predictability of funding for capex, dividends and debt service. This reduces planning visibility and increases refinancing or liquidity risk, making the company's financial profile more fragile over a 2-6 month horizon.
Novolog News
NVLG FAQ
What was Novolog (Pharm UP 1966) Ltd.’s price range in the past 12 months?
Novolog (Pharm UP 1966) Ltd. lowest stock price was 79.10 and its highest was 154.63 in the past 12 months.
What is Novolog (Pharm UP 1966) Ltd.’s market cap?
Novolog (Pharm UP 1966) Ltd.’s market cap is ₪408.70M.
When is Novolog (Pharm UP 1966) Ltd.’s upcoming earnings report date?
Novolog (Pharm UP 1966) Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 67 days.
How were Novolog (Pharm UP 1966) Ltd.’s earnings last quarter?
Novolog (Pharm UP 1966) Ltd. released its earnings results on May 25, 2026. The company reported 0.1 earnings per share for the quarter, beating the consensus estimate of N/A by 0.1.
Is Novolog (Pharm UP 1966) Ltd. overvalued?
According to Wall Street analysts Novolog (Pharm UP 1966) Ltd.’s price is currently Overvalued.
Does Novolog (Pharm UP 1966) Ltd. pay dividends?
Novolog (Pharm UP 1966) Ltd. pays a Quarterly dividend of 1.957 which represents an annual dividend yield of 3.05%. See more information on Novolog (Pharm UP 1966) Ltd. dividends here
What is Novolog (Pharm UP 1966) Ltd.’s EPS estimate?
Novolog (Pharm UP 1966) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novolog (Pharm UP 1966) Ltd. have?
Novolog (Pharm UP 1966) Ltd. has 510,874,760 shares outstanding.
What happened to Novolog (Pharm UP 1966) Ltd.’s price movement after its last earnings report?
Novolog (Pharm UP 1966) Ltd. reported an EPS of 0.1 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.078%.
Which hedge fund is a major shareholder of Novolog (Pharm UP 1966) Ltd.?
Currently, no hedge funds are holding shares in IL:NVLG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novolog (Pharm UP 1966) Ltd.
Novolog (Pharm-Up 1966) Ltd, operating from its headquarters in Modi'in-Maccabim-Re'ut, Israel, offers a comprehensive suite of healthcare solutions. The company is involved in distributing critical medical equipment to both clinical establishments and individuals receiving care at home. It also provides essential medical logistics support for businesses within the pharmaceutical and medical device sectors. Beyond direct provisions, Novolog develops bespoke treatment plans and arranges for nurses to conduct home visits. It plays a role in public and professional health education by generating and circulating valuable medical information and practical resources. Furthermore, the firm extends its expertise to corporate clients, offering management services for their health and medical processes. Novolog also specializes in the sterilization of medical and laboratory items using ethylene oxide gas and facilitates direct engagement with the health and wellness ecosystem for international enterprises.